These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21831734)

  • 21. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
    Taïeb J; Lecomte T; Aparicio T; Asnacios A; Mansourbakht T; Artru P; Fallik D; Spano JP; Landi B; Lledo G; Desrame J
    Ann Oncol; 2007 Mar; 18(3):498-503. PubMed ID: 17158774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
    Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
    Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Maiello E; Giuliani F; Borsellino N; Arcara C; Colucci G
    Am J Clin Oncol; 2010 Oct; 33(5):461-4. PubMed ID: 20142727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
    Collot T; Fumet JD; Klopfenstein Q; Vincent J; Bengrine L; Ghiringhelli F
    Anticancer Res; 2018 Oct; 38(10):5963-5968. PubMed ID: 30275226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line irinotecan combined with 5-fluorouracil and leucovorin for high-grade metastatic gastrointestinal neuroendocrine carcinoma.
    Du Z; Wang Y; Zhou Y; Wen F; Li Q
    Tumori; 2013; 99(1):57-60. PubMed ID: 23549001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy for gastro-enteropancreatic endocrine tumours.
    O'Toole D; Hentic O; Corcos O; Ruszniewski P
    Neuroendocrinology; 2004; 80 Suppl 1():79-84. PubMed ID: 15477723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
    Kulke MH; Wu B; Ryan DP; Enzinger PC; Zhu AX; Clark JW; Earle CC; Michelini A; Fuchs CS
    Dig Dis Sci; 2006 Jun; 51(6):1033-8. PubMed ID: 16865563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
    Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
    Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
    J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
    Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
    Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
    Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
    Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
    Claringbold PG; Turner JH
    Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
    Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
    Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
    Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
    Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
    Schempf U; Sipos B; König C; Malek NP; Bitzer M; Plentz RR
    Z Gastroenterol; 2014 Feb; 52(2):200-3. PubMed ID: 24526405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.